Scintigraphic evaluation of a novel colon-targeted delivery system (CODES) in healthy volunteers.

The purposes of this study are to investigate the gastrointestinal transit and release properties of a novel, colon-targeted delivery system (CODES) administered to healthy volunteers using gamma scintigraphy and to confirm that lactulose functions to promote disintegration in the colon. Two placebo formulations were studied: one was CODES, which consisted of a lactulose containing core overcoated with both Eudragit E and Eudragit L designed to rapidly disintegrate in the colon, the other was lactulose-free reference formulation (LFRF) that consisted of lactulose-free tablet core overcoated with the same materials. Transit and disintegration of the radiolabeled formulations were followed by gamma scintigraphy. In the fasted state, scintigraphic images indicated that CODES started to disintegrate in the ascending colon in the majority of subjects at 7.11 +/- 2.01 h post-dose. Disintegration was complete within 1 h following commencement of in vivo release. In contrast, LFRF presented with prolonged in vivo disintegration properties. In the fed state, the disintegration period of CODES was almost comparable to that observed in the fasted state. Gamma scintigraphic studies clearly showed that CODES provides for rapid target site release in the colon regardless of the ingestion of food.

[1]  P. Tothill,et al.  Gastric emptying of solids in man. , 1982, Gut.

[2]  A. Gazzaniga,et al.  Oral delayed-release system for colonic specific delivery☆ , 1994 .

[3]  Jinhe Li,et al.  Effect of Colonic Lactulose Availability on the Timing of Drug Release Onset in Vivo from a Unique Colon-Specific Drug Delivery System (CODES™) , 2003, Pharmaceutical Research.

[4]  Clive G. Wilson,et al.  A comparative study of the gastrointestinal transit of a pellet and tablet formulation , 1984 .

[5]  L. C. Feely,et al.  Gastrointestinal transit of non-disintegrating tablets in fed subjects , 1989 .

[6]  S. Davis,et al.  Alimentary tract andpancreas Transit ofpharmaceutical dosage forms through the , 1986 .

[7]  J. N. Hunt,et al.  The volume and energy content of meals as determinants of gastric emptying. , 1975, The Journal of physiology.

[8]  I. Wilding,et al.  The Use of Scintigraphy to Provide 'Proof of Concept' for Novel Polysaccharide Preparations Designed for Colonic Drug Delivery , 2004, Pharmaceutical Research.

[9]  I. Wilding,et al.  Variation in Gastrointestinal Transit of Pharmaceutical Dosage Forms in Healthy Subjects , 1991, Pharmaceutical Research.

[10]  I. Wilding,et al.  The Effect of Meal Composition on the Gastrocolonic Response: Implications for Drug Delivery to the Colon , 1993, Pharmaceutical Research.

[11]  D. Neckers,et al.  A new approach to the oral administration of insulin and other peptide drugs. , 1986, Science.

[12]  R. Khosla,et al.  The effect of tablet size on the gastric emptying of non-disintegrating tablets , 1990 .

[13]  Hitoshi Kawai,et al.  Studies on lactulose formulations for colon-specific drug delivery. , 2002, International journal of pharmaceutics.

[14]  S. I. Kim,et al.  Linear type azo-containing polyurethane as drug-coating material for colon-specific delivery: its properties, degradation behavior, and utilization for drug formulation. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[15]  Characterization of colonic transit of nondisintegrating tablets in healthy subjects , 1993, Digestive Diseases and Sciences.

[16]  I. Wilding,et al.  Colonic transit of different sized tablets in healthy subjects , 1993 .

[17]  Masao Kobayashi,et al.  Preparation of enteric coated timed-release press-coated tablets and evaluation of their function by in vitro and in vivo tests for colon targeting. , 2000, International journal of pharmaceutics.

[18]  I. Wilding,et al.  The effect of food on the gastrointestinal transit and systemic absorption of naproxen from a novel sustained release formulation , 1995 .

[19]  K. Takada,et al.  Evaluation of intestinal pressure-controlled colon delivery capsule containing caffeine as a model drug in human volunteers. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[20]  M. Marvola,et al.  Gastrointestinal Transit and Concomitant Absorption of Verapamil from a Single-Unit Sustained-Release Tablet , 1987 .